Free Trial
NASDAQ:EVOK

Evoke Pharma Q1 2025 Earnings Report

Evoke Pharma logo
$2.58 -0.01 (-0.54%)
As of 04/25/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Evoke Pharma EPS Results

Actual EPS
N/A
Consensus EPS
-$0.33
Beat/Miss
N/A
One Year Ago EPS
N/A

Evoke Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
$3.32 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Evoke Pharma Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Tuesday, May 13, 2025
Conference Call Time
4:00PM ET

Conference Call Resources

Evoke Pharma Earnings Headlines

Evoke Pharma (NASDAQ:EVOK) Coverage Initiated at StockNews.com
Evoke Pharma, Inc. (NASDAQ:EVOK) Short Interest Update
Crypto’s crashing…but we’re still profiting
Most traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess. The news is screaming fear. But while most traders watch their portfolios tank…
Q4 2024 Evoke Pharma Inc Earnings Call
See More Evoke Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Evoke Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Evoke Pharma and other key companies, straight to your email.

About Evoke Pharma

Evoke Pharma (NASDAQ:EVOK), a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

View Evoke Pharma Profile

More Earnings Resources from MarketBeat